Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.

MLA

Karmali, Reem, et al. “Impact of Treatment Variability on Survival in Immuno-Competent and Immuno-Compromised Patients with Primary Central Nervous Lymphoma.” British Journal of Haematology, vol. 177, no. 1, Apr. 2017, pp. 72–79. EBSCOhost, https://doi.org/10.1111/bjh.14522.

APA

Karmali, R., Nabhan, C., Petrich, A. M., Raizer, J., Peace, D., Lukas, R., Gordon, L. I., Basu, S., Chukkapalli, V., & Venugopal, P. (2017). Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. British Journal of Haematology, 177(1), 72–79. https://doi.org/10.1111/bjh.14522

Chicago

Karmali, Reem, Chadi Nabhan, Adam M. Petrich, Jeffrey Raizer, David Peace, Rimas Lukas, Leo I. Gordon, Sanjib Basu, Vineela Chukkapalli, and Parameswaran Venugopal. 2017. “Impact of Treatment Variability on Survival in Immuno-Competent and Immuno-Compromised Patients with Primary Central Nervous Lymphoma.” British Journal of Haematology 177 (1): 72–79. doi:10.1111/bjh.14522.